Free Trial
NASDAQ:EDSA

Edesa Biotech (EDSA) Stock Price, News & Analysis

Edesa Biotech logo
$2.75 -0.13 (-4.51%)
Closing price 04:00 PM Eastern
Extended Trading
$2.74 0.00 (-0.18%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Edesa Biotech Stock (NASDAQ:EDSA)

Advanced

Key Stats

Today's Range
$2.70
$2.89
50-Day Range
$2.09
$2.88
52-Week Range
$1.55
$4.49
Volume
74,984 shs
Average Volume
649,336 shs
Market Capitalization
$19.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Moderate Buy

Company Overview

Edesa Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

EDSA MarketRank™: 

Edesa Biotech scored higher than 52% of companies evaluated by MarketBeat, and ranked 543rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Edesa Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Edesa Biotech has a consensus price target of $5.00, representing about 80.5% upside from its current price of $2.77.

  • Amount of Analyst Coverage

    Edesa Biotech has only been the subject of 1 research reports in the past 90 days.

  • Read more about Edesa Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Edesa Biotech are expected to grow in the coming year, from ($1.75) to ($1.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Edesa Biotech is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Edesa Biotech is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Edesa Biotech has a P/B Ratio of 4.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Edesa Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    0.13% of the float of Edesa Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Edesa Biotech has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Edesa Biotech has recently decreased by 17.86%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Edesa Biotech does not currently pay a dividend.

  • Dividend Growth

    Edesa Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.13% of the float of Edesa Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Edesa Biotech has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Edesa Biotech has recently decreased by 17.86%, indicating that investor sentiment is improving significantly.
  • Search Interest

    1 people have searched for EDSA on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Edesa Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.60% of the stock of Edesa Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 5.50% of the stock of Edesa Biotech is held by institutions.

  • Read more about Edesa Biotech's insider trading history.
Receive EDSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edesa Biotech and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EDSA Stock News Headlines

Edesa Biotech Launches At-The-Market Offering Program
EDSA: EB06 Manufacturing to be Completed by End of 2025…
An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
Edesa Biotech Posts Narrower Loss in Q3
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
See More Headlines

EDSA Stock Analysis - Frequently Asked Questions

Edesa Biotech's stock was trading at $1.68 at the start of the year. Since then, EDSA shares have increased by 64.9% and is now trading at $2.77.

Edesa Biotech, Inc. (NASDAQ:EDSA) announced its earnings results on Friday, August, 8th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01.

Edesa Biotech shares reverse split before market open on Wednesday, October 11th 2023.The 1-7 reverse split was announced on Tuesday, October 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Shares of EDSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Edesa Biotech investors own include Pfizer (PFE), Ford Motor (F), Moderna (MRNA), Occidental Petroleum (OXY), Plug Power (PLUG), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/08/2025
Today
10/07/2025
Next Earnings (Estimated)
12/12/2025
Fiscal Year End
9/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EDSA
CIK
1540159
Employees
20
Year Founded
2015

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+76.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.17 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-162.95%
Return on Assets
-60.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
18.96
Quick Ratio
18.96

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.61 per share
Price / Book
4.65

Miscellaneous

Outstanding Shares
7,038,000
Free Float
5,447,000
Market Cap
$19.95 million
Optionable
Not Optionable
Beta
0.07

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:EDSA) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners